Enanta Pharmaceuticals
Stock Forecast, Prediction & Price Target
Enanta Pharmaceuticals Financial Estimates
Enanta Pharmaceuticals Revenue Estimates
Enanta Pharmaceuticals EBITDA Estimates
Enanta Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 9/30/2022 | 9/30/2023 | 9/30/2024 | 9/30/2025 | 9/30/2026 | 9/30/2027 | 9/30/2028 |
Revenue
% change YoY
| $86.16M N/A | $79.20M -8.07% | $67.63M -14.60% | Avg: $72.54M Low: $59.53M High: $106.04M avg. 7.25% | Avg: $69.79M Low: $62.84M High: $88.84M avg. -3.78% | Avg: $135.42M Low: $121.93M High: $172.38M avg. 94.03% | Avg: $220.49M Low: $198.52M High: $280.67M avg. 62.81% |
Net Income
% change YoY
| $-121.75M N/A | $-133.81M -9.90% | $-116.04M 13.28% | Avg: $-114.80M Low: $-128.74M High: $-85.34M avg. 1.06% | Avg: $-135.17M Low: $-167.33M High: $-66.05M avg. -17.74% | Avg: $-86.11M Low: $-116.66M High: $-74.95M avg. 36.29% | Avg: $-80.94M Low: $-109.65M High: $-70.45M avg. 6.00% |
EBITDA
% change YoY
| $-120.95M N/A | $-123.47M -2.08% | $-104.51M 15.35% | Avg: $-45.86M Low: $-67.03M High: $-37.63M avg. 56.11% | Avg: $-44.12M Low: $-56.16M High: $-39.72M avg. 3.78% | Avg: $-85.61M Low: $-108.98M High: $-77.08M avg. -94.03% | Avg: $-139.39M Low: $-177.43M High: $-125.50M avg. -62.81% |
EPS
% change YoY
| -$5.91 N/A | -$6.38 -7.95% | -$5.48 14.10% | Avg: -$5 Low: -$6.14 High: -$4.07 avg. 8.84% | Avg: -$5.06 Low: -$7.98 High: -$3.15 avg. -1.28% | Avg: -$4.11 Low: -$5.56 High: -$3.57 avg. 18.83% | Avg: -$3.86 Low: -$5.23 High: -$3.36 avg. 6.00% |
Operating Expenses
% change YoY
| $210.00M N/A | $216.41M 3.05% | $189.32M -12.51% | Avg: $27.30M Low: $22.41M High: $39.91M avg. -85.57% | Avg: $26.27M Low: $23.65M High: $33.44M avg. -3.78% | Avg: $50.97M Low: $45.89M High: $64.88M avg. 94.03% | Avg: $82.99M Low: $74.72M High: $105.64M avg. 62.81% |
FAQ
What is Enanta Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 6.40% in 2025-2028.
We have gathered data from 6 analysts. Their low estimate is -128.74M, average is -114.80M and high is -85.34M.
What is Enanta Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 40.07% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $59.53M, average is $72.54M and high is $106.04M.
What is Enanta Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 8.09% in 2025-2028.
We have gathered data from 6 analysts. Their low earnings per share estimate is -$6.14, average is -$5 and high is $-4.07.
What is the best performing analyst?
In the last twelve months analysts have been covering Enanta Pharmaceuticals stock. The most successful analyst is Yasmeen Rahimi.